Maxion Therapeutics strengthens its Board with the appointment of Ian Tomlinson (Chairman), Tom Weaver (Non-Executive Director), and Aneesh Karatt Vellatt (Director)
Maxion Therapeutics, a biotechnology company developing novel biologics that target ion channels and GPCRs, today announced the appointment of Ian Tomlinson, PhD, Tom Weaver, PhD and Aneesh Karatt Vellatt, PhD, to the board of directors. The new directors will be guiding Maxion in the next phase of its development, using its revolutionary KnotBody® technology platform to establish a portfolio of first-in-class therapeutic candidates against traditionally intractable targets.
Ian Tomlinson, PhD
Thomas Weaver, PhD
Aneesh Karatt Vellatt, PhD
Dr Ian Tomlinson, who will be chairing Maxion’s board of directors, has over 30 years of experience in life sciences, from academic research to biotech start-up to big pharma. Dr Tomlinson co-founded Domantis with Sir Gregory Winter, which was acquired by GSK in 2007 for $454 million. He then served as Senior VP, Head of Worldwide Business Development and Head of Biopharm R&D at GSK. He is also Founding Director and SAB Chair for Apollo Therapeutics (a unique venture dedicated to turning academic science into cutting edge medicines) and Chair of Start Codon (a life sciences venture builder based in Cambridge).
Non-executive Director, Dr Tom Weaver, is an expert in technology development and scaling science platforms. He also has been involved in forming and growing companies, including Hexagen Genetics (acquired by Incyte), Geneservice (acquired by Source Biosciece), Congenica and Next Gen Diagnostics (both still private). Dr Weaver is currently also the co-founder and CEO of PetMedix, an antibody therapeutics company in animal health.
Maxion’s Chief Scientific Officer and co-founder, Dr Aneesh Karatt Vellatt, has also been appointed to the board. Dr Karatt Vellatt holds a PhD in Biochemistry from the University of Cambridge and was previously co-founder of IONTAS Ltd. He has over 10 years of experience in antibody and protein drug discovery against challenging targets at AstraZeneca, the University of Cambridge, and IONTAS.
Contact
About Maxion Therapeutics
Maxion Therapeutics is a biotechnology company developing antibody-based drugs for previously untreatable ion channel- and G protein-coupled receptor (GPCR)-driven diseases, including autoimmune conditions, chronic pain, and cardiovascular disease.
The Company is developing a pipeline of potentially first- and best-in-class therapeutics using its proprietary KnotBody® technology to generate potent, selective, and long-acting therapeutics by combining naturally occurring mini-proteins (‘knottins’) with antibodies using state-of-the-art phage and mammalian display technologies. Maxion was founded in 2020 by highly respected biotech entrepreneurs and scientists Dr John McCafferty, CTO and Dr Aneesh Karatt-Vellatt, CSO. Dr McCafferty previously co-invented antibody phage display, which was the subject of the 2018 Nobel Prize in Chemistry awarded to his co-inventor Sir Gregory Winter. Maxion’s portfolio and growth is being advanced by a team of highly experienced leaders in the discovery and development of antibody-based drugs. The Company is based near Cambridge, UK and is backed by international blue-chip investors.
For more information, please visit: https://www.maxiontherapeutics.com/
